PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Robert Dreicer, MD, MS, MACP, FASCO/Pedro C. Barata, MD, MSc - Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer
Go online to PeerView.com/TGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the multidisciplinary relationship between urologic oncologists and advanced practice clinicians in the management of patients with prostate cancer has become increasingly more important in providing the best patient care. During this video, an expert panel highlights how a multidisciplinary team can use the latest clinical evidence, treatment guidelines, and expert consensus recommendations to improve care for patients with prostate cancer and gives practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. The experts also provide meaningful guidance to assist clinicians in optimizing treatment planning based on a modern understanding of prostate cancer biology, best treatment practices, and the expanding opportunities for treatment personalization across the disease continuum. Upon completion of this CE activity, participants will be able to: Implement guideline recommendations related to genetic testing when managing patients with prostate cancer, Apply current evidence about available and emerging anti-androgen and non-hormonal agents when deciding on treatment for prostate cancer, Integrate appropriate anti-androgen and non-hormonal strategies into treatment plans for patients with prostate cancer.